01—Abstract
Summary
Summary of the 8-K filed September 9, 2025. Cited figures are marked; the original filing is the authoritative source.
Johnson & Johnson's September 9, 2025 Form 8-K reports the election of John Morikis to its Board of Directors, announced September 8, 2025.
Mr. Morikis is the retired Executive Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, where he led the company from 2016 to 2024. The Board has determined that he meets the independence requirements of the NYSE Listed Company Manual. He will serve on the Audit Committee and the Compensation & Benefits Committee.
This is a governance event, not a financial one. The filing contains no earnings, revenue, guidance, or balance sheet information, and it does not describe any change in JNJ's strategy or operations. Mr. Morikis will receive standard non-employee director compensation, as described in the Director Compensation section of the 2025 Proxy Statement, and the filing does not disclose specific pay terms.
For investors, the appointment is a modest signal. Johnson & Johnson is adding an experienced public-company CEO with global operations and supply chain expertise, and placing him on the Audit and Compensation committees, which oversee financial reporting and executive pay. The impact on the stock is likely to be minimal.
02—Key points
Key Highlights
- Board addition: John Morikis was elected to Johnson & Johnson's Board of Directors, with the announcement made on September 8, 2025.
- Independence confirmed: The Board determined that Mr. Morikis meets the independence requirements of the NYSE Listed Company Manual.
- Committee assignments: He will serve on the Audit Committee and the Compensation & Benefits Committee, two key oversight bodies.
- Relevant background: He served as Executive Chairman, President and CEO of The Sherwin-Williams Company from 2016 to 2024 and spent about four decades at that company, including eight years as CEO.
- Operational experience: Per the press release, he led Sherwin-Williams' global expansion to 123 countries, supply chain optimization, and technology investments, which Johnson & Johnson's CEO cited as relevant to global markets and complex supply chains.
- Compensation: As a non-employee director, he will receive compensation described in the 2025 Proxy Statement; no specific amounts are disclosed in this filing.
- No financial impact disclosed: The filing contains no financial results, guidance, or material transactions.
03—Questions
Frequently Asked Questions
Does this 8-K change Johnson & Johnson's financial outlook?
No. The filing covers only a board appointment and includes no financial results, guidance, or material transactions. Investors should look to JNJ's earnings releases and periodic reports for financial performance.
Who is John Morikis and why is he relevant to J&J?
He is the retired Executive Chairman, President and CEO of The Sherwin-Williams Company, where he worked from 1984 and led the company from 2016 to 2024. J&J's CEO, Joaquin Duato, cited his experience leading a large multinational organization, understanding of global markets and complex supply chains, and use of technology to drive innovation.
Why does it matter that he joins the Audit and Compensation & Benefits Committees?
The Audit Committee oversees financial reporting, internal controls, and the independent auditor, while the Compensation & Benefits Committee oversees executive pay and benefits. Serving on these committees gives him direct involvement in key areas of corporate governance.
Is he considered independent?
Yes. The Board determined that Mr. Morikis satisfies the independence requirements of the NYSE Listed Company Manual, which is required for committee service on these committees.
How much will he be paid as a director?
The filing says he will receive compensation as described in the Director Compensation section of the Company's 2025 Proxy Statement. Specific amounts are not disclosed in this 8-K.
04—Continue